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People living in areas with stable transmission of P. falciparum parasites acquire 15 
protective immunity to malaria over a number of years and following multiple disease 16 
episodes. Immunity acquired this way is mediated by IgG with specificity for parasite-17 
encoded, clonally variant surface antigens (VSA) on the surface of infected erythrocytes 18 
(IEs). However, women in endemic areas become susceptible to P. falciparum infection 19 
when they become pregnant, particularly for the first time, regardless of previously 20 
acquired protective immunity. This conundrum was resolved when it was observed that 21 
the selective placental accumulation of IEs that characterizes pregnancy-associated 22 
malaria (PAM) is caused by an immunologically and functionally unique subset of VSA 23 
(VSAPAM) that is only expressed by parasites infecting pregnant women, and that 24 
protective immunity to PAM is mediated by IgG with specificity for VSAPAM. In this 25 
review we summarize the research leading to the identification of the distinctly 26 
structured PfEMP1 variant VAR2CSA as the dominant PAM-type VSA and as the 27 
clinically most important target of the protective immune response to placental 28 
P. falciparum infection. 29 
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Plasmodium falciparum malaria is both the commonest and most serious form of 34 
malaria affecting humans, and is an infection of colossal medical and economic 35 
consequence (Sachs and Malaney 2002; Miller et al. 2002; Greenwood and 36 
Mutabingwa 2002). In areas of intense parasite transmission, severe P. falciparum 37 
malaria is concentrated among infants and young children, because acquisition of 38 
protective immunity causes malaria-related mortality and severe morbidity to decrease 39 
with increasing age. However, development of immunity is slow, and substantial 40 
protection is only achieved after a number of disease episodes. Even then, immunity is 41 
partial, and though severe morbidity is rare among adults, sterile protection is probably 42 
never achieved. Several studies have documented the efficacy of passive immunization 43 
of malaria patients with IgG from clinically immune adults, showing that antibodies 44 
targeting asexual blood-stage antigens are an important component of protective 45 
immunity acquired following natural exposure to P. falciparum parasites (Cohen, 46 
McGregor and Carrington 1961; McGregor, Carrington and Cohen 1963; Sabchareon et 47 
al. 1991). Trans-placental transfer of IgG also seems to be responsible for resistance to 48 
malaria for the first months of life in infants born to clinically immune mothers (Bruce-49 
Chwatt 1952). Antibodies with specificity for a number of antigens expressed by 50 
asexual blood-stage parasites are likely to contribute to this protection. However, 51 
parasite-encoded, clonally variant surface antigens (VSA) expressed on the surface of 52 
the infected erythrocytes (IEs) appear to be of particular importance (Marsh et al. 1989), 53 
and the intra- and inter-clonal diversity of VSA go a long way towards explaining the 54 
sluggish acquisition of immunological protection (reviewed by Hviid 2005). The 55 
general rule of P. falciparum malaria as a childhood disease in areas of intense parasite 56 
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transmission has one important exception that has attracted substantial attention in 57 
recent years: pregnancy-associated malaria (PAM). 58 
PREGNANCY-ASSOCIATED MALARIA 59 
It is a long-recognized fact that pregnant women are at increased risk of malaria, with 60 
adverse maternal and foetal consequences (reviewed by Duffy and Desowitz 2001). 61 
This pregnancy-related susceptibility is apparent despite previously acquired protective 62 
immunity, and even in malaria-endemic areas, P. falciparum infection is therefore both 63 
more prevalent and more severe in pregnant women than in their non-pregnant peers 64 
(Walton 1949). It has often been speculated that PAM is an unavoidable consequence of 65 
maternal immuno-suppression or -modulation to protect the foetal allograft from 66 
rejection (Menendez 1995). However, pregnancy-induced immune modulation mainly 67 
affects the cellular arm of immunity, whereas humoral immunity (upon which 68 
protection from malaria hinges) is largely unaffected (reviewed by Guilbert, Abbasi and 69 
Mosmann 2001). Furthermore, susceptibility to PAM is concentrated among women of 70 
low parity, in particular primigravidae (McGregor 1984). This suggests that 71 
susceptibility to PAM is due to a specific absence of immunity to a particular form or 72 
subset of P. falciparum parasites that can only infect pregnant women, and that 73 
protection against PAM-specific parasites is acquired following exposure to them 74 
during pregnancy in a manner similar to acquisition of protection from malaria in 75 
general. The hypothesis of a pregnancy-specific subset of P. falciparum is further 76 
supported by the facts that PAM is characterized by a selective accumulation of IEs in 77 
the placenta (Blacklock and Gordon 1925) and that pregnancy-associated parasitaemia 78 
generally resolves spontaneously shortly after expulsion of the placenta at 79 
delivery (Nguyen-Dinh et al. 1988).  80 
 5
PAM is caused by functionally and immunologically unique parasites 81 
Erythrocytes infected by mature (trophozoite and schizont) stages of P. falciparum 82 
parasites can bind to a range of different receptors in the host vasculature. The first 83 
adhesion receptor identified was CD36 (Barnwell, Ockenhouse and Knowles, II 1985; 84 
Ockenhouse et al. 1989), followed by a range of other molecules, including the 85 
proteoglycan chondroitin sulphate A (CSA) (Rogerson et al. 1995; Robert et al. 1995). 86 
The first direct piece of evidence in favour of the hypothesis of a discrete parasite subset 87 
being responsible for PAM was the finding that IEs isolated from the placenta of 88 
women with PAM exclusively bind to CSA, a receptor that is rarely – if ever – 89 
exploited as an adhesion receptor by P. falciparum-IEs in non-PAM infections (Fried 90 
and Duffy 1996). This key observation was followed by the similarly important 91 
observation that placental and CSA-adhering IEs are not only functionally but also 92 
immunologically distinct from all other IEs (Fried et al. 1998; Beeson et al. 1999; Ricke 93 
et al. 2000). As adhesion of IEs in general is mediated by VSA, these findings together 94 
pointed to a functionally and immunologically distinct subset of VSA that is exclusively 95 
expressed by placental and CSA-adhering parasites; a subset often referred to as 96 
VSAPAM.   97 
Protective immunity to PAM is mediated by IgG with specificity for PAM-specific 98 
VSA  99 
It is generally suspected that protective immunity to malaria depends on VSA-specific 100 
IgG that can interfere with receptor-specific IE adhesion (David et al. 1983; Udeinya et 101 
al. 1983), and that the piecemeal acquisition of protective immunity to malaria reflects 102 
the need to acquire a broad repertoire of such antibodies with specificity for a multitude 103 
of antigenically distinct VSA (Marsh and Howard 1986; Bull et al. 1998).  The 104 
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importance of VSAPAM in protective immunity against PAM was therefore reinforced 105 
when it was shown that serum antibodies can inhibit adhesion of IEs to CSA in a parity-106 
dependent manner (Fried et al. 1998; Ricke et al. 2000). In addition to inhibition of IE 107 
adhesion, opsonization and phagocytosis of IEs may also play an important role in 108 
protective immunity to PAM. The dominance of cytophilic subclasses among VSAPAM-109 
specific IgG (Megnekou et al. 2005; Elliott et al. 2005) and the finding of impaired 110 
opsonization of VSAPAM-expressing IEs in HIV-infected women (Mount et al. 2004; 111 
Keen et al. 2006) support this possibility. In any case, levels of VSAPAM-specific IgG at 112 
delivery correlate inversely with placental parasitaemia (Staalsoe et al. 2001), and direct 113 
and compelling evidence of the clinical importance of CSA adhesion-inhibitory as well 114 
as VSAPAM-specific IgG have recently become available (Duffy and Fried 2003; 115 
Staalsoe et al. 2004). 116 
Molecular identification of VSAPAM, 117 
Most efforts to identify VSAPAM in molecular terms have focused on the best-described 118 
family of VSA, P. falciparum erythrocyte membrane protein 1 (PfEMP1) (Leech et al. 119 
1984). These high-molecular weight antigens are encoded by the var multi-gene family 120 
(Baruch et al. 1995; Su et al. 1995; Smith et al. 1995). Scherf et al. (1998) observed 121 
transcription of a particular var gene, dubbed varCSA, in P. falciparum FCR3 selected for 122 
IE adhesion to CSA, and the Duffy-binding-like (DBL) 3- domain of the encoded 123 
PfEMP1 variant was found to have affinity for CSA (Buffet et al. 1999). Most 124 
P. falciparum genomes contain a var gene very similar to varCSA, and these related 125 
genes were grouped together in the var1csa sub-family of var genes (Salanti et al. 2002; 126 
Rowe et al. 2002). These findings, and the observation that var1csa is often highly 127 
transcribed by placental parasites (Fried and Duffy 2002), fitted the earlier prediction 128 
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(Fried et al. 1998) that the antigen mediating IE adhesion to CSA, and the suspected 129 
target of PAM-specific immunity, was conserved between parasite clones. However, a 130 
number of other findings do not support the hypothesis of VAR1CSA as a PAM-type 131 
VSA, or its involvement as a target of protective immunity against PAM. Thus, high 132 
transcription of var1csa is not restricted to placental and CSA-adhering parasites (Rowe 133 
et al. 2002; Kyes et al. 2003), and levels of VAR1CSA-specific IgG do not correlate 134 
with gender or parity, in contrast to expectation regarding VSAPAM-specific IgG (Jensen 135 
et al. 2003). Finally, the ability of IEs to adhere to CSA is maintained after disruption of 136 
var1csa (Andrews et al. 2003).  137 
An unusually structured gene, var2csa, is selectively transcribed by CSA-adhering 138 
and placental parasites 139 
The availability of the complete P. falciparum genome (Gardner et al. 2002) opened the 140 
possibility of more precise analysis of var gene transcription than had previously been 141 
possible with degenerate primers (Taylor et al. 2000). Taking this approach, Salanti et 142 
al. (2003) analyzed changes in var gene transcription in response to selection of NF54-143 
IEs for adhesion to CSA, which resulted in acquisition of the VSAPAM-type gender-144 
specific and parity-dependent IgG recognition pattern of selected IEs (Ricke et al. 145 
2000). The striking result was that the selection resulted in markedly increased and 146 
dominant transcription of a single, distinctly structured, var gene, PFL0030c (Salanti et 147 
al. 2003). PFE1640w, which belongs to the var1csa sub-family previously implicated in 148 
adhesion of IE to CSA, is a pseudo-gene in NF54/3D7, but data from other parasite 149 
lines have shown that selection for IE adhesion to CSA does not increase the abundance 150 
of var1csa transcripts (Salanti et al. 2003). Genes with high similarity to PFL0030c, and 151 
now grouped in the var2csa sub-family, appear to be present in all P. falciparum clones 152 
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and to be selectively transcribed by CSA-selected and placental parasites alike (Salanti 153 
et al. 2003; Duffy et al. 2005; Tuikue Ndam et al. 2005). The findings that several 154 
VAR2CSA domains have affinity for CSA (Gamain et al. 2005) and that disruption of 155 
var2csa interferes with the ability to acquire the CSA-adhering phenotype further 156 
supports the PAM-relevance of this sub-family (Viebig et al. 2005; Duffy et al. 2006). 157 
It is noteworthy that the var2csa response to CSA-selection had gone unnoticed in 158 
earlier studies because they used degenerate primers targeting DBL1- or DBL1- 159 
encoding sequences (Taylor et al. 2000; Fried and Duffy 2002); domains that are not 160 
present in VAR2CSA. 161 
VAR2CSA has the characteristics expected of VSAPAM  162 
The distinct structure of var2csa compared to other var genes corresponded well with 163 
the expected functional and antigenic uniqueness of the PAM-type VSA it was assumed 164 
to encode (Lavstsen et al. 2003; Kraemer and Smith 2003). Indeed, analysis of levels of 165 
VAR2CSA-specific IgG in P. falciparum-exposed adults confirmed the female-166 
restricted and parity-dependent pattern expected of VSAPAM (Salanti et al. 2004). 167 
Importantly, VAR2CSA is present on the surface of intact VSAPAM-type IEs and absent 168 
from the surface of IEs that do not have this phenotype (Salanti et al. 2004; Barfod et al. 169 
2006). Finally, we have shown that high plasma levels of VAR2CSA-specific IgG 170 
correlate with protection from adverse clinical consequences of PAM (Salanti et al. 171 
2004).  172 
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VAR2CSA appears to be the dominant target of the protective immune response to 173 
PAM 174 
The importance of VSA-specific IgG relative to IgG with other antigen specificities for 175 
clinical protection against P. falciparum malaria is unknown, but may be high (Marsh et 176 
al. 1989). A parallel issue is the importance of IgG with specificity for VAR2CSA 177 
relative to other VSAPAM specificities in protection against PAM. To address this latter 178 
question, we cloned memory B cells from recently pregnant, P. falciparum-exposed 179 
multigravidae, using a recently developed and highly efficient immortalization method 180 
(Traggiai et al. 2004). The clones were subsequently screened for production of 181 
VSAPAM-specific monoclonal IgG using a panel of IEs displaying the VSAPAM 182 
phenotype. All except one of the eight VSAPAM-specific monoclonals had specificity for 183 
either the DBL3-X or the DBL5- domain of VAR2CSA (Barfod et al. 2006). The 184 
characteristics of the remaining antibody suggest that it is also VAR2CSA-specific. 185 
Although var2csa is composed of alternating stretches of substantial and restricted 186 
interclonal diversity (Salanti et al. 2003; Trimnell et al. 2006; Dahlbäck et al. 2006), all 187 
the human monoclonal IgG antibodies targeted polymorphic rather than conserved 188 
epitopes (Barfod et al. 2006). This finding suggests that domains of IE surface-189 
expressed VAR2CSA that are accessible to protective antibodies are under selection 190 
pressure that favours polymorphism, in agreement with conclusions drawn from in 191 
silico analysis of var2csa (Trimnell et al. 2006; Dahlbäck et al. 2006). This pressure is 192 
most likely due to protective host immunity, supporting the clinical significance of the 193 
VAR2CSA-specific IgG response to PAM. 194 
 10
CONCLUDING REMARKS 195 
VAR1CSA (as well as several non-PfEMP1 antigens) continues to be implicated in the 196 
pathogenesis as well as in the protective immune response to pregnancy-specific 197 
P. falciparum infection (Chia et al. 2005; Badaut et al. 2006), and is being explored as a 198 
candidate for development of vaccines against PAM (Gamain et al. 2004; Chia et al. 199 
2005; Bir et al. 2006). However, from our perspective the bulk of current evidence 200 
identifies VAR2CSA as the main antigen mediating placental sequestration of 201 
P. falciparum-IEs and as the dominant and clinically most relevant target of the human 202 
IgG response to placental P. falciparum infection. 203 
ACKNOWLEDGEMENTS 204 
The PAM-specific research at Centre for Medical Parasitology receives financial 205 
support from the Bill and Melinda Gates Foundation, the Commission of the European 206 
Communities, the European Malaria Vaccine Initiative, the Danish Medical Research 207 




Andrews, K. T., Pirrit, L. A., Przyborski, J. M., Sanchez, C. P., Sterkers, Y., 211 
Ricken, S., Wickert, H., Lepolard, C., Avril, M., Scherf, A., Gysin, J. and 212 
Lanzer, M. (2003). Recovery of adhesion to chondroitin-4-sulphate in Plasmodium 213 
falciparum var CSA disruption mutants by antigenically similar PfEMP1 variants. 214 
Molecular Microbiology 49, 655-669. 215 
Badaut, C., Faure, G., Tuikue Ndam, N. G., Bertin, G., Chaffotte, A., Khattab, A., 216 
Klinkert, M.-Q., Deloron, P. and Bentley, G. A. Receptor-binding studies of the 217 
DBL domain of Plasmodium falciparum erythrocyte membrane protein 1 from a 218 
placental isolate. Molecular and Biochemical Parasitology, (in press). 219 
Barfod, L., Bernasconi, N., Dahlbäck, M., Jarrosay, D., Andersen, P. H., Salanti, 220 
A., Ofori, M. F., Turner, L., Resende, M., Nielsen, M. A., Theander, T. G., 221 
Sallusto, F., Lanzavecchia, A. and Hviid, L. Human pregnancy-associated malaria-222 
specific B cells target polymorphic, conformational epitopes in VAR2CSA. 223 
Molecular Microbiology, (in press). 224 
Barnwell, J. W., Ockenhouse, C. F. and Knowles, D. M., II. (1985). Monoclonal 225 
antibody OKM5 inhibits the in vitro binding of Plasmodium falciparum infected 226 
erythrocytes to monocytes, endothelial, and C32 melanoma cells. Journal of 227 
Immunology 135, 3494-3497. 228 
Baruch, D. I., Pasloske, B. L., Singh, H. B., Bi, X., Ma, X. C., Feldman, M., 229 
Taraschi, T. F. and Howard, R. J. (1995). Cloning the P. falciparum gene 230 
encoding PfEMP1, a malarial variant antigen and adherence receptor on the surface 231 
of parasitized human erythrocytes. Cell 82, 77-87. 232 
 12
Beeson, J. G., Brown, G. V., Molyneux, M. E., Mhango, C., Dzinjalamala, F. and 233 
Rogerson, S. J. (1999). Plasmodium falciparum isolates from infected pregnant 234 
women and children are associated with distinct adhesive and antigenic properties. 235 
Journal of Infectious Diseases 180, 464-472. 236 
Bir, N., Yazdani, S. S., Avril, M., Layez, C., Gysin, J. and Chitnis, C. E. (2006). 237 
Immunogenicity of Duffy binding-like domains that bind chondroitin sulfate A and 238 
protection against pregnancy-associated malaria. Infection and Immunity 74, 5955-239 
5963. 240 
Blacklock, B. and Gordon, R. M. (1925). Malaria parasites in the placental blood. 241 
Annals of Tropical Medicine 19, 37-45. 242 
Bruce-Chwatt, L. J. (1952). Malaria in African infants and children in southern 243 
Nigeria. Annals of Tropical Medicine and Parasitology 46, 173-200. 244 
Buffet, P. A., Gamain, B., Scheidig, C., Baruch, D., Smith, J. D., Hernandez-Rivas, 245 
R., Pouvelle, B., Oishi, S., Fujii, N., Fusai, T., Parzy, D., Miller, L. H., Gysin, J. 246 
and Scherf, A. (1999). Plasmodium falciparum domain mediating adhesion to 247 
chondroitin sulfate A: a receptor for human placental infection. Proceedings of the 248 
National Academy of Sciences of the United States of America 96, 12743-12748. 249 
Bull, P. C., Lowe, B. S., Kortok, M., Molyneux, C. S., Newbold, C. I. and Marsh, K. 250 
(1998). Parasite antigens on the infected red cell are targets for naturally acquired 251 
immunity to malaria. Nature Medicine 4, 358-360. 252 
Chia, Y.-S., Badaut, C., Tuikue Ndam, N. G., Khattab, A., Igonet, S., Fievet, N., 253 
Bentley, G. A., Deloron, P. and Klinkert, M.-Q. (2005). Functional and 254 
immunological characterization of a Duffy binding-like- domain from Plasmodium 255 
 13
falciparum erythrocyte membrane protein-1 expressed by a placental isolate. Journal 256 
of Infectious Diseases 192, 1284-1293. 257 
Cohen, S., McGregor, I. A. and Carrington, S. (1961). Gammaglobulin and acquired 258 
immunity to human malaria. Nature 192, 733-737. 259 
Dahlbäck, M., Rask, T. S., Andersen, P. H., Nielsen, M. A., Tuikue-Ndam, N. G., 260 
Resende, M., Turner, L., Deloron, P., Hviid, L., Lund, O., Pedersen, A. G., 261 
Theander, T. G. and Salanti, A. (2006). Epitope mapping and topographic analysis 262 
of VAR2CSA DBL3X involved in Plasmodium falciparum placental sequestration. 263 
PLoS Pathogens 2, e124. 264 
David, P. H., Hommel, M., Miller, L. H., Udeinya, I. J. and Oligino, L. D. (1983). 265 
Parasite sequestration in Plasmodium falciparum malaria: spleen and antibody 266 
modulation of cytoadherence of infected erythrocytes. Proceedings of the National 267 
Academy of Sciences of the United States of America 80, 5075-5079. 268 
Duffy, M. F., Byrne, T. J., Elliott, S. R., Wilson, D. W., Rogerson, S. J., Beeson, J. 269 
G., Noviyanti, R. and Brown, G. V. (2005). Broad analysis reveals a consistent 270 
pattern of var gene transcription in Plasmodium falciparum repeatedly selected for a 271 
defined adhesion phenotype. Molecular Microbiology 56, 774-788. 272 
Duffy, M. F., Maier, A. G., Byrne, T. J., Marty, A. J., Elliott, S. R., O'Neill, M. T., 273 
Payne, P. D., Rogerson, S. J., Cowman, A. F., Crabb, B. S. and Brown, G. V. 274 
(2006). VAR2CSA is the principal ligand for chondroitin sulfate A in two allogeneic 275 
isolates of Plasmodium falciparum. Molecular and Biochemical Parasitology 148, 276 
117-124. 277 
 14
Duffy, P. E. and R. S. Desowitz (2001). Pregnancy malaria throughout history: 278 
dangerous labors, p. 1-25. In P. E. Duffy and M. Fried (ed.), Malaria in pregnancy. 279 
Deadly parasite, susceptible host. Taylor & Francis, London. 280 
Duffy, P. E. and Fried, M. (2003). Antibodies that inhibit Plasmodium falciparum 281 
adhesion to chondroitin sulfate A are associated with increased birth weight and the 282 
gestational age of newborns. Infection and Immunity 71, 6620-6623. 283 
Elliott, S. R., Brennan, A. K., Beeson, J. G., Tadesse, E., Molyneux, M. E., Brown, 284 
G. V. and Rogerson, S. J. (2005). Placental malaria induces variant-specific 285 
antibodies of the cytophilic subtypes immunoglobulin G1 (IgG1) and IgG3 that 286 
correlate with adhesion inhibitory activity. Infection and Immunity 73, 5903-5907. 287 
Fried, M. and Duffy, P. E. (2002). Two DBL subtypes are commonly expressed by 288 
placental isolates of Plasmodium falciparum. Molecular and Biochemical 289 
Parasitology 122, 201-210. 290 
Fried, M. and Duffy, P. E. (1996). Adherence of Plasmodium falciparum to 291 
chondroitin sulphate A in the human placenta. Science 272, 1502-1504. 292 
Fried, M., Nosten, F., Brockman, A., Brabin, B. T. and Duffy, P. E. (1998). 293 
Maternal antibodies block malaria. Nature 395, 851-852. 294 
Gamain, B., Smith, J. D., Avril, M., Baruch, D. I., Scherf, A., Gysin, J. and Miller, 295 
L. H. (2004). Identification of a 67-amino-acid region of the Plasmodium falciparum 296 
variant surface antigen that binds chondroitin sulphate A and elicits antibodies 297 
reactive with the surface of placental isolates. Molecular Microbiology 53, 445-455. 298 
Gamain, B., Trimnell, A. R., Scheidig, C., Scherf, A., Miller, L. H. and Smith, J. D. 299 
(2005). Identification of multiple chondroitin sulfate A (CSA)-binding domains in 300 
 15
the var2CSA gene transcribed in CSA-binding parasites. Journal of Infectious 301 
Diseases 191, 1010-1013. 302 
Gardner, M. J., Hall, N., Fung, E., White, O., Berriman, M., Hyman, R. W., 303 
Carlton, J. M., Pain, A., Nelson, K. E., Bowman, S., Paulsen, I. T., James, K., 304 
Eisen, J. A., Rutherford, K., Salzberg, S. L., Craig, A., Kyes, S., Chan, M. S., 305 
Nene, V., Shallom, S. J., Suh, B., Peterson, J., Angiuoli, S., Pertea, M., Allen, J., 306 
Selengut, J., Haft, D., Mather, M. W., Vaidya, A. B., Martin, D. M., Fairlamb, 307 
A. H., Fraunholz, M. J., Roos, D. S., Ralph, S. A., McFadden, G. I., Cummings, 308 
L. M., Subramanian, G. M., Mungall, C., Venter, J. C., Carucci, D. J., Hoffman, 309 
S. L., Newbold, C., Davis, R. W., Fraser, C. M. and Barrell, B. (2002). Genome 310 
sequence of the human malaria parasite Plasmodium falciparum. Nature 419, 498-311 
511. 312 
Greenwood, B. and Mutabingwa, T. (2002). Malaria in 2002. Nature 415, 670-672. 313 
Guilbert, L. J., M. Abbasi, and T. R. Mosmann (2001). The immunology of 314 
pregnancy: maternal defenses against infectious diseases, p. 53-70. In P. E. Duffy 315 
and M. Fried (ed.), Malaria in pregnancy. Deadly parasite, susceptible host. Taylor & 316 
Francis, London. 317 
Hviid, L. (2005). Naturally acquired immunity to Plasmodium falciparum malaria in 318 
Africa. Acta Tropica 95, 270-275. 319 
Jensen, A. T. R., Zornig, H. D., Buhmann, C., Salanti, A., Koram, K. A., Riley, E. 320 
M., Theander, T. G., Hviid, L. and Staalsoe, T. (2003). Lack of gender-specific 321 
antibody recognition of products from domains of a var gene implicated in 322 
pregnancy-associated Plasmodium falciparum malaria. Infection and Immunity 71, 323 
4193-4196. 324 
 16
Keen, J., Serghides, L., Ayi, K., Patel, S. N., Ayisi, J., van Eijk, A., Steketee, R., 325 
Udhayakumar, V. and Kain, K. C. HIV impairs phagocytic clearance of 326 
pregnancy-associated malaria parasites. PLoS Medicine, (in press). 327 
Kraemer, S. M. and Smith, J. D. (2003). Evidence for the importance of genetic 328 
structuring to the structural and functional specialization of the Plasmodium 329 
falciparum var gene family. Molecular Microbiology 50, 1527-1538. 330 
Kyes, S. A., Christodoulou, Z., Raza, A., Horrocks, P., Pinches, R., Rowe, J. A. and 331 
Newbold, C. I. (2003). A well-conserved Plasmodium falciparum var gene shows an 332 
unusual stage-specific transcript pattern. Molecular Microbiology 48, 1339-1348. 333 
Lavstsen, T., Salanti, A., Jensen, A. T. R., Arnot, D. E. and Theander, T. G. (2003). 334 
Sub-grouping of Plasmodium falciparum 3D7 var genes based on sequence analysis 335 
of coding and non-coding regions. Malaria Journal 2, 27. 336 
Leech, J. H., Barnwell, J. W., Miller, L. H. and Howard, R. J. (1984). Identification 337 
of a strain-specific malarial antigen exposed on the surface of Plasmodium 338 
falciparum-infected erythrocytes. Journal of Experimental Medicine 159, 1567-1575. 339 
Marsh, K. and Howard, R. J. (1986). Antigens induced on erythrocytes by P. 340 
falciparum: expression of diverse and conserved determinants. Science 231, 150-153. 341 
Marsh, K., Otoo, L., Hayes, R. J., Carson, D. C. and Greenwood, B. M. (1989). 342 
Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and 343 
their relation to protection against infection. Transactions of the Royal Society of 344 
Tropical Medicine and Hygiene 83, 293-303. 345 
McGregor, I. A. (1984). Epidemiology, malaria and pregnancy. American Journal of 346 
Tropical Medicine and Hygiene 33, 517-525. 347 
 17
McGregor, I. A., Carrington, S. P. and Cohen, S. (1963). Treatment of East African 348 
P. falciparum malaria with West African human -globulin. Transactions of the 349 
Royal Society of Tropical Medicine and Hygiene 57, 170-175. 350 
Megnekou, R., Staalsoe, T., Taylor, D. W., Leke, R. and Hviid, L. (2005). Effects of 351 
pregnancy and intensity of Plasmodium falciparum transmission on immunoglobulin 352 
G subclass responses to variant surface antigens. Infection and Immunity 73, 4112-353 
4118. 354 
Menendez, C. (1995). Malaria during pregnancy: a priority area of malaria research and 355 
control. Parasitology Today 11, 178-183. 356 
Miller, L. H., Baruch, D. I., Marsh, K. and Doumbo, O. K. (2002). The pathogenic 357 
basis of malaria. Nature 415, 673-679. 358 
Mount, A. M., Mwapasa, V., Elliott, S. R., Beeson, J. G., Tadesse, E., Lema, V. M., 359 
Molyneux, M. E., Meshnick, S. R. and Rogerson, S. J. (2004). Impairment of 360 
humoral immunity to Plasmodium falciparum malaria in pregnancy by HIV 361 
infection. Lancet 363, 1860-1867. 362 
Nguyen-Dinh, P., Steketee, R. W., Greenberg, A. E., Wirima, J. J., Mulenda, O. 363 
and Williams, S. B. (1988). Rapid spontaneous postpartum clearance of 364 
Plasmodium falciparum parasitaemia in African women. Lancet 2, 751-752. 365 
Ockenhouse, C. F., Tandon, N. N., Magowan, C., Jamieson, G. A. and Chulay, J. 366 
D. (1989). Identification of a platelet membrane glycoprotein as a falciparum malaria 367 
sequestration receptor. Science 243, 1469-1471. 368 
Ricke, C. H., Staalsoe, T., Koram, K., Akanmori, B. D., Riley, E. M., Theander, T. 369 
G. and Hviid, L. (2000). Plasma antibodies from malaria-exposed pregnant women 370 
recognize variant surface antigens on Plasmodium falciparum-infected erythrocytes 371 
 18
in a parity-dependent manner and block parasite adhesion to chondroitin sulphate A. 372 
Journal of Immunology 165, 3309-3316. 373 
Robert, C., Pouvelle, B., Meyer, P., Muanza, K., Fujioka, H., Aikawa, M., Scherf, 374 
A. and Gysin, J. (1995). Chondroitin-4-sulphate (proteoglycan), a receptor for 375 
Plasmodium falciparum-infected erythrocyte adherence on brain microvascular 376 
endothelial cells. Research in Immunology 146, 383-393. 377 
Rogerson, S. J., Chaiyaroj, S. C., Ng, K., Reeder, J. C. and Brown, G. V. (1995). 378 
Chondroitin sulfate A is a cell surface receptor for Plasmodium falciparum-infected 379 
erythrocytes. Journal of Experimental Medicine 182, 15-20. 380 
Rowe, J. A., Kyes, S. A., Rogerson, S. J., Babiker, H. A. and Raza, A. (2002). 381 
Identification of a conserved Plasmodium falciparum var gene implicated in malaria 382 
in pregnancy. Journal of Infectious Diseases 185, 1207-1211. 383 
Sabchareon, A., Burnouf, T., Ouattara, D., Attanath, P., Bouharoun, T. H., 384 
Chantavanich, P., Foucault, C., Chongsuphajaisiddhi, T. and Druilhe, P. (1991). 385 
Parasitologic and clinical human response to immunoglobulin administration in 386 
falciparum malaria. American Journal of Tropical Medicine and Hygiene 45, 297-387 
308. 388 
Sachs, J. and Malaney, P. (2002). The economic and social burden of malaria. Nature 389 
415, 680-685. 390 
Salanti, A., Dahlbäck, M., Turner, L., Nielsen, M. A., Barfod, L., Magistrado, P., 391 
Jensen, A. T. R., Lavstsen, T., Ofori, M. F., Marsh, K., Hviid, L. and Theander, 392 
T. G. (2004). Evidence for the involvement of VAR2CSA in pregnancy-associated 393 
malaria. Journal of Experimental Medicine 200, 1197-1203. 394 
 19
Salanti, A., Jensen, A. T. R., Zornig, H. D., Staalsoe, T., Joergensen, L., Nielsen, M. 395 
A., Khattab, A., Arnot, D. E., Klinkert, M. Q., Hviid, L. and Theander, T. G. 396 
(2002). A sub-family of common and highly conserved var genes expressed by CSA-397 
adhering Plasmodium falciparum. Molecular and Biochemical Parasitology 122, 398 
111-115. 399 
Salanti, A., Staalsoe, T., Lavstsen, T., Jensen, A. T. R., Sowa, M. P. K., Arnot, D. 400 
E., Hviid, L. and Theander, T. G. (2003). Selective upregulation of a single 401 
distinctly structured var gene in CSA-adhering Plasmodium falciparum involved in 402 
pregnancy-associated malaria. Molecular Microbiology 49, 179-191. 403 
Scherf, A., Hernandez-Rivas, R., Buffet, P., Bottius, E., Benatar, C., Pouvelle, B., 404 
Gysin, J. and Lanzer, M. (1998). Antigenic variation in malaria: in situ switching, 405 
relaxed and mutually exclusive transcription of var genes during intra-erythrocytic 406 
development in Plasmodium falciparum. EMBO Journal 17, 5418-5428. 407 
Smith, J. D., Chitnis, C. E., Craig, A. G., Roberts, D. J., Hudson-Taylor, D. E., 408 
Peterson, D. S., Pinches, R., Newbold, C. I. and Miller, L. H. (1995). Switches in 409 
expression of Plasmodium falciparum var genes correlate with changes in antigenic 410 
and cytoadherent phenotypes of infected erythrocytes. Cell 82, 101-110. 411 
Staalsoe, T., Megnekou, R., Fievet, N., Ricke, C. H., Zornig, H. D., Leke, R., 412 
Taylor, D. W., Deloron, P. and Hviid, L. (2001). Acquisition and decay of 413 
antibodies to pregnancy-associated variant antigens on the surface of Plasmodium 414 
falciparum infected erythrocytes that are associated with protection against placental 415 
parasitemia. Journal of Infectious Diseases 184, 618-626. 416 
Staalsoe, T., Shulman, C. E., Bulmer, J. N., Kawuondo, K., Marsh, K. and Hviid, 417 
L. (2004). Variant surface antigen-specific IgG and protection against the clinical 418 
 20
consequences of pregnancy-associated Plasmodium falciparum malaria. Lancet 363, 419 
283-289. 420 
Su, X., Heatwole, V. M., Wertheimer, S. P., Guinet, F., Herrfeldt, J. A., Peterson, 421 
D. S., Ravetch, J. A. and Wellems, T. E. (1995). The large diverse gene family var 422 
encodes proteins involved in cytoadherence and antigenic variation of Plasmodium 423 
falciparum-infected erythrocytes. Cell 82, 89-100. 424 
Taylor, H. M., Kyes, S. A., Harris, D., Kriek, N. and Newbold, C. I. (2000). A study 425 
of var gene transcription in vitro using universal var gene primers. Molecular and 426 
Biochemical Parasitology 105, 13-23. 427 
Traggiai, E., Becker, S., Subbarao, K., Kolesnikova, L., Uematsu, Y., Gismondo, 428 
M. R., Murphy, B. R., Rappuoli, R. and Lanzavecchia, A. (2004). An efficient 429 
method to make human monoclonal antibodies from memory B cells: potent 430 
neutralization of SARS coronavirus. Nature Medicine 10, 871-875. 431 
Trimnell, A. R., Kraemer, S. M., Mukherjee, S., Phippard, D. J., Janes, J. H., 432 
Flamoe, E., Su, X. Z., Awadalla, P. and Smith, J. D. (2006). Global genetic 433 
diversity and evolution of var genes associated with placental and severe childhood 434 
malaria. Molecular and Biochemical Parasitology 148, 169-180. 435 
Tuikue Ndam, N. G., Salanti, A., Bertin, G., Dahlbäck, M., Fievet, N., Turner, L., 436 
Gaye, A., Theander, T. G. and Deloron, P. (2005). High level of var2csa 437 
transcription by Plasmodium falciparum isolated from the placenta. Journal of 438 
Infectious Diseases 192, 331-335. 439 
Udeinya, I. J., Miller, L. H., McGregor, I. A. and Jensen, J. B. (1983). Plasmodium 440 
falciparum strain-specific antibody blocks binding of infected erythrocytes to 441 
amelanotic melanoma cells. Nature 303, 429-431. 442 
 21
Viebig, N. K., Gamain, B., Scheidig, C., Lepolard, C., Przyborski, J., Lanzer, M., 443 
Gysin, J. and Scherf, A. (2005). A single member of the Plasmodium falciparum 444 
var multigene family determines cytoadhesion to the placental receptor chondroitin 445 
sulphate A. EMBO Reports 6, 775-781. 446 
Walton, G. A. (1949). On the control of malaria in Freetown, Sierra Leone. II - control 447 
methods and the effects upon the transmission of Plasmodium falciparum resulting 448 
from the reduced abundance of Anopheles gambiae. Annals of Tropical Medicine 449 
and Parasitology 43, 117-139. 450 
 451 
 452 
